X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): DSP107,Azacitidine
Therapeutic Area: Oncology Product Name: DSP107
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Cancer Focus Fund
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding May 26, 2021
Details:
DSP107 uniquely delivers a multilayered attack by binding cancer cells and T-cells to produce a targeted synergistic effect, combining immune checkpoint inhibition with selective T-cell activation.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Naptumomab estafenatox,Durvalumab
Therapeutic Area: Oncology Product Name: NAP
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2021
Details:
Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
